Duchenne muscular dystrophy (DMD) is a severe muscle wasting X-linked genetic disease caused by dystrophin gene mutations. Gene replacement therapy aims to transfer a functional full-length dystrophin cDNA or a quasi micro/mini-gene into the muscle. A number of AAV vectors carrying microdystrophin genes have been tested in the mdx model of DMD. Further modification/optimization of these microgene vectors may improve the therapeutic potency. In this chapter, we describe a species-specific, codon optimization protocol to improve microdystrophin gene therapy in the mdx model.
CITATION STYLE
Athanasopoulos, T., Foster, H., Foster, K., & Dickson, G. (2011). Codon Optimization of the Microdystrophin Gene for Duchenne Muscular Dystrophy Gene Therapy. In Methods in Molecular Biology (Vol. 709, pp. 21–37). Humana Press Inc. https://doi.org/10.1007/978-1-61737-982-6_2
Mendeley helps you to discover research relevant for your work.